DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases
Melanoma is one of the tumor types with the highest risk of brain metastasis. However, the biology of melanoma brain metastasis and the role of the brain immune microenvironment in treatment responses are not yet fully understood. Using preclinical models and single-cell transcriptomics, we have identified a mechanism that enhances antitumor immunity in melanoma brain metastasis. We show that activation of the Rela/Nuclear Factor κB (NF-κB) pathway in microglia promotes melanoma brain metastasis. Targeting this pathway elicits microglia reprogramming toward a proinflammatory phenotype, which enhances antitumor immunity and reduces brain metastatic burden. Furthermore, we found that proinflammatory microglial markers in melanoma brain metastasis are associated with improved responses to immune checkpoint inhibitors in patients and targeting Rela/NF-κB pathway in mice improves responses to these therapies in the brain, suggesting a strategy to enhance antitumor immunity and responses to immune checkpoint inhibitors in patients with melanoma brain metastasis., We thank Angela Nieto for helpful discussions and suggestions along the project and the preparation of the manuscript and AG.de-la-Fuente for advice and assistance, particularly with flow cytometry experiments. We thank the Core Facilities and animal house for the technical support (Verona Villar, Giovanna Exposito, Antonio Caler, Josep Mulet, and Alvaro Fenoll). We thank Prof. Angel Barco for the Relatm1Asba mice, Prof. Larue for the 1014 cells, and the MD Anderson Foundation Biobank. This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, co-financed by ERDF (MICINN-AEI, PID2022-141613OB-I00 [B.S-L.]; PID2021-129053OB-100 [J.P.L-A.]; PID2022-136854OB-I00 [G.M-B.]) and ISCIII (CIBERONC, CB16/12/00295 [G.M-B.]); the FERO Foundation [B.S-L.]; and Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.91574 [B.S-L.]). F.J.R-B. held an GVA-APOSTD21 contract. We also acknowledge support from ICAR and the GEM group [B.S-L.] and the GVA (CIPROM/2021/045 [B.S.-L.] and PROMETEO/2020/007 [J.P.L-A.]), CSIC PTI-NEURO-AGING +, and Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033. Illustrations were created with BioRender., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-141613OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-129053OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136854OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 CEX2021-001165-S
DOI: http://hdl.handle.net/10261/387676, https://api.elsevier.com/content/abstract/scopus_id/85218857329
HANDLE: http://hdl.handle.net/10261/387676, https://api.elsevier.com/content/abstract/scopus_id/85218857329